Switch theme
Sign up to access all valuation multiples
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
2018
150
LTM Revenue $49.0M
Last FY EBITDA -$111M
-$67.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Century Therapeutics has a last 12-month revenue (LTM) of $49.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Century Therapeutics achieved revenue of $6.6M and an EBITDA of -$111M.
Century Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Century Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $49.0M | XXX | $6.6M | XXX | XXX | XXX |
| Gross Profit | $49.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$111M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1692% | XXX | XXX | XXX |
| EBIT | -$104M | XXX | -$134M | XXX | XXX | XXX |
| EBIT Margin | -211% | XXX | -2031% | XXX | XXX | XXX |
| Net Profit | -$93.6M | XXX | -$127M | XXX | XXX | XXX |
| Net Margin | -191% | XXX | -1921% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Century Therapeutics's stock price is $1.
Century Therapeutics has current market cap of $45.2M, and EV of -$67.2M.
See Century Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$67.2M | $45.2M | XXX | XXX | XXX | XXX | $-1.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Century Therapeutics has market cap of $45.2M and EV of -$67.2M.
Century Therapeutics's trades at -10.2x EV/Revenue multiple, and 0.6x EV/EBITDA.
Equity research analysts estimate Century Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Century Therapeutics has a P/E ratio of -0.5x.
See valuation multiples for Century Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $45.2M | XXX | $45.2M | XXX | XXX | XXX |
| EV (current) | -$67.2M | XXX | -$67.2M | XXX | XXX | XXX |
| EV/Revenue | -1.4x | XXX | -10.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBIT | 0.6x | XXX | 0.5x | XXX | XXX | XXX |
| EV/Gross Profit | -1.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.5x | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCentury Therapeutics's last 12 month revenue growth is 31%
Century Therapeutics's revenue per employee in the last FY averaged $44K, while opex per employee averaged $0.9M for the same period.
Century Therapeutics's rule of 40 is -5393% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Century Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Century Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1692% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -5393% | XXX | -1661% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1628% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2131% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Century Therapeutics acquired XXX companies to date.
Last acquisition by Century Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Century Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Century Therapeutics founded? | Century Therapeutics was founded in 2018. |
| Where is Century Therapeutics headquartered? | Century Therapeutics is headquartered in United States of America. |
| How many employees does Century Therapeutics have? | As of today, Century Therapeutics has 150 employees. |
| Who is the CEO of Century Therapeutics? | Century Therapeutics's CEO is Mr. Brent Pfeiffenberger, M.B.A.,PhD. |
| Is Century Therapeutics publicy listed? | Yes, Century Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Century Therapeutics? | Century Therapeutics trades under IPSC ticker. |
| When did Century Therapeutics go public? | Century Therapeutics went public in 2021. |
| Who are competitors of Century Therapeutics? | Similar companies to Century Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Century Therapeutics? | Century Therapeutics's current market cap is $45.2M |
| What is the current revenue of Century Therapeutics? | Century Therapeutics's last 12 months revenue is $49.0M. |
| What is the current revenue growth of Century Therapeutics? | Century Therapeutics revenue growth (NTM/LTM) is 31%. |
| What is the current EV/Revenue multiple of Century Therapeutics? | Current revenue multiple of Century Therapeutics is -1.4x. |
| Is Century Therapeutics profitable? | Yes, Century Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
